Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

XTL Biopharmaceuticals Ltd. Director's Dealing 2007

Aug 22, 2007

7116_rns_2007-08-22_a0712608-661c-4ea0-8eba-e807b510aeca.htm

Director's Dealing

Open in viewer

Opens in your device viewer



_________

C004אקס טי אל ביופרמסוטיקלס בע"מ2PublicX T L BIOPHARMACEUTICALS LTD4313Corporation no: 520039470Stock Exchange/Market: אקס טי אל1996352Hasapir 3 , Nes Ziona 76100 , ,Tel: 08-9304444 , Fax: 08-9304445E.mail address: [email protected] of transmission: 22/08/2007              Time of broadcast: 10:08 09:58:54

Reference: 2007-02-366820

Israel Securities Authority Tel Aviv Stock Exchange
www.isa.gov.il www.tase.co.il

Immediate report on other matterDon't use this form if there is more adequate one

Company's CEO Ron Bentsur, purchaded yesterday a total of 15,279 American Depositary Receipts (ADRs) at an average price of $1.30 per ADR. This brings his direct holdings up to 20,101 ADRs. Company's Director of Finance Bill Kessler, purchaded yesterday a total of 5,000 ADRs at an average price of $1.29 per ADR. This brings his direct holdings up to 5,000 ADRs. Each ADR equals to 10 ordinary shares of the Company.
Attached file _________
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 28/06/2007
- - -
Name of the Signatory: : Kantor Ronen , , Position of Signatory in the reporting corporation: Legal Consultant & Corporate Secretary
Abba Hillel Silver Telephone: 03-6133371 , Facsimile: 03-6133372 , E-mail: [email protected]